Masimo Corporation

Report azionario NasdaqGS:MASI

Capitalizzazione di mercato: US$9.4b

Masimo Crescita futura

Criteri Future verificati 1/6

Si prevede che Masimo aumenterà gli utili e i ricavi rispettivamente del 12.4% e 6.3% all'anno, mentre si prevede che l'EPS crescerà del 11.5% all'anno.

Informazioni chiave

12.4%

Tasso di crescita degli utili

11.48%

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili16.1%
Tasso di crescita dei ricavi6.3%
Rendimento futuro del capitale proprion/a
Copertura analitica

Good

Ultimo aggiornamento28 Apr 2026

Aggiornamenti recenti sulla crescita futura

Recent updates

Aggiornamento della narrazione • May 12

MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns

Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.
Aggiornamento della narrazione • Apr 23

MASI: Danaher Cash Offer And Legal And Deal Completion Risks Will Dominate

The analyst fair value estimate for Masimo has been adjusted from $177 to $180, with analysts pointing to the agreed $180 per share cash acquisition by Danaher as the key anchor for updated price targets and ratings. Analyst Commentary Recent research on Masimo has shifted from growth driven valuation debates to a focus on the agreed US$180 per share cash offer from Danaher as the primary reference point for fair value and ratings.
Aggiornamento della narrazione • Apr 09

MASI: Danaher Cash Offer And Legal Outcomes Will Steer Deal Path

The analyst price target for Masimo has been trimmed by about $1.60 to $177.00, as analysts factor in a slightly higher discount rate and a modestly lower future P/E, while aligning expectations with the $180 per share cash acquisition offer from Danaher. Analyst Commentary Recent research on Masimo has become highly focused on the agreed cash acquisition by Danaher at $180 per share, with most coverage shifting from long term growth narratives to deal related outcomes and near term valuation anchor points.
Aggiornamento della narrazione • Mar 25

MASI: Danaher Cash Offer And Patent Rulings Will Shape Deal Outcome

Analysts kept Masimo's fair value estimate steady at $178.60 while aligning their price targets around the agreed $180 per share cash acquisition by Danaher, with recent rating changes reflecting the view that any potential upside is now largely tied to the deal closing as planned. Analyst Commentary Recent research on Masimo centers on the agreed US$180 per share cash offer from Danaher, with ratings and targets now clustered around that level.
Aggiornamento della narrazione • Mar 05

MASI: Danaher Cash Deal And Legal Overhang Will Frame Future Returns

The updated analyst price target for Masimo edges down by $0.15 to $178.60, as analysts anchor their views to Danaher's agreed $180 per share cash acquisition and recent rating moves to Neutral or No Rating. Analyst Commentary Recent research around Masimo has centered on the agreed US$180 per share cash acquisition by Danaher, with most analysts reframing their views around deal completion rather than standalone upside or downside.
Aggiornamento della narrazione • Feb 18

MASI: Danaher Cash Buyout Will Define Future Returns And Key Risks

Analysts have trimmed their Masimo fair value estimate from $183.13 to $178.75 to align expectations with the agreed $180 per share cash acquisition by Danaher. This shift is reflected in new Hold and Neutral ratings that are centered around the $180 level.
Seeking Alpha • Feb 17

Masimo: Danaher Acquisition Saves The Company From Lackluster Performance

Summary Masimo Corporation agreed to be acquired by Danaher for $180/share, valuing MASI at $9.9B. The acquisition offers a strong strategic fit, combining MASI's non-invasive oximetry with DHR's invasive diagnostics for comprehensive acute care solutions. Shareholders benefit from a 34% stock price surge and a potential 2.8% spread to deal close, with minimal market risk. Holding MASI shares until the deal closes offers a relatively safe, low-stress return, though opportunity cost and regulatory risk remain. Read the full article on Seeking Alpha
Aggiornamento della narrazione • Nov 21

MASI: Renewed Philips Partnership Will Drive Outperformance Despite Market Challenges

Analysts have adjusted their price target for Masimo downward from approximately $188 to $183. This change is attributed to shifts in revenue growth estimates and a strengthening profit margin following recent partnership developments and ongoing market challenges.
Articolo di analisi • Sep 12

Is Masimo Corporation (NASDAQ:MASI) Potentially Undervalued?

Masimo Corporation ( NASDAQ:MASI ), might not be a large cap stock, but it received a lot of attention from a...
Articolo di analisi • Aug 01

Calculating The Fair Value Of Masimo Corporation (NASDAQ:MASI)

Key Insights Using the 2 Stage Free Cash Flow to Equity, Masimo fair value estimate is US$136 Masimo's US$154 share...
Articolo di analisi • Jun 19

Is Masimo (NASDAQ:MASI) Using Too Much Debt?

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Articolo di analisi • May 29

Is It Time To Consider Buying Masimo Corporation (NASDAQ:MASI)?

Masimo Corporation ( NASDAQ:MASI ), is not the largest company out there, but it saw significant share price movement...
Seeking Alpha • Apr 25

Masimo: Priced Dearly Given Uncertainty

Summary Masimo Corporation, a mid-cap healthcare firm, has a new CEO and is navigating considerable uncertainty. Some aspects of the company's divestiture of its consumer business are still unclear. Despite this, the stock is generally well liked within the analyst firm community, following solid Q4 results. An analysis around Masimo Corporation follows in the paragraphs below. Read the full article on Seeking Alpha
Seeking Alpha • Dec 11

Masimo: A Stellar Performance After The Dust Has Settled

Summary Masimo's proxy fight and Sound United acquisition distracted from the core business, but resolution and focus on healthcare are driving value and momentum. Shares surged over 50% since July due to strong Q2 results and improved earnings guidance, despite ongoing challenges and leadership changes. Current valuations are demanding, suggesting an opportune time for profit taking, while I maintain a position for long-term growth potential. Divesting Sound United could reduce debt, enhancing focus on the core med-tech business with promising double-digit organic growth. Read the full article on Seeking Alpha
Seeking Alpha • Sep 25

Masimo Corporation: Too Much Uncertainty For Now

Summary Masimo Corporation's stock has underperformed, with shares down 6% versus SPY's 15% increase, due to mixed margins and lack of meaningful catalysts. The company's financials show low ROA, ROE, and ROTC, with tight margins and a concerning interest coverage ratio of 2.6x. The sale of Sound United and recent partnerships with Google and Qualcomm offer potential, but the future growth sustainability remains uncertain. Internal management struggles and recent board shakeup add to the volatility, making me cautious and opting to stay on the sidelines for now. Read the full article on Seeking Alpha
User avatar
Nuova narrazione • Aug 28

Sensors Surge And Decisive Shifts Set To Soar In Healthcare Triumph

Increased hospital admissions and successful hospital conversions to Masimo products are anticipated to continue driving healthcare revenue growth.

Previsioni di crescita degli utili e dei ricavi

NasdaqGS:MASI - Stime future degli analisti e dati finanziari passati (USD Millions )
DataRicaviUtiliFlusso di cassa liberoLiquidità dell'operazioneAvg. Numero di analisti
12/31/20281,850302N/AN/A1
12/31/20271,747297N/AN/A6
12/31/20261,628260N/AN/A2
4/4/20261,559217206232N/A
1/3/20261,527208193218N/A
9/27/20252,182-240168208N/A
6/28/20252,154-270134177N/A
3/29/20251,42831150182N/A
12/28/20241,39516158196N/A
9/28/20241,576115171223N/A
6/29/20241,711101125190N/A
3/30/20241,8239259140N/A
12/30/20231,2761083294N/A
9/30/20232,11689-5810N/A
7/1/20232,187116-2828N/A
4/1/20232,297118-457N/A
12/31/20222,036144-2729N/A
10/1/20221,74617178134N/A
7/2/20221,505191147205N/A
4/2/20221,244223181229N/A
1/1/20221,239230230265N/A
10/2/20211,207232188232N/A
7/3/20211,177224149190N/A
4/3/20211,173229176228N/A
1/2/20211,144240131211N/A
9/26/20201,096223138217N/A
6/27/20201,047222148227N/A
3/28/2020976211N/A222N/A
12/28/2019938196N/A222N/A
9/28/2019913190N/A215N/A
6/29/2019895198N/A212N/A
3/30/2019877197N/A210N/A
12/29/2018858194N/A240N/A
9/29/2018843139N/A225N/A
6/30/2018826118N/A199N/A
3/31/2018807119N/A114N/A
12/30/2017790125N/A56N/A
9/30/2017766348N/A338N/A
7/1/2017740340N/A347N/A
4/1/2017720325N/A414N/A
12/31/2016713311N/A419N/A
10/1/2016672109N/A150N/A
7/2/2016657101N/A145N/A
4/2/201664090N/A117N/A
1/2/201662383N/A117N/A
10/3/201562380N/A85N/A
7/4/201561376N/A86N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: La crescita prevista degli utili di MASI ( 12.4% all'anno) è superiore al tasso di risparmio ( 3.5% ).

Guadagni vs Mercato: Si prevede che gli utili di MASI ( 12.4% all'anno) cresceranno più lentamente rispetto al mercato US ( 16.9% all'anno).

Guadagni ad alta crescita: Si prevede che gli utili di MASI cresceranno, ma non in modo significativo.

Ricavi vs Mercato: Si prevede che il fatturato di MASI ( 6.3% all'anno) crescerà più lentamente rispetto al mercato US ( 11.9% all'anno).

Ricavi ad alta crescita: Si prevede che il fatturato di MASI ( 6.3% all'anno) crescerà più lentamente di 20% all'anno.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Dati insufficienti per determinare se il Return on Equity di MASI è previsto essere elevato tra 3 anni

Scoprire le aziende in crescita

7D

1Y

7D

1Y

7D

1Y

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/27 15:29
Prezzo dell'azione a fine giornata2026/05/27 00:00
Utili2026/04/04
Utili annuali2026/01/03

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Masimo Corporation è coperta da 22 analisti. 6 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Michael PolarkBaird
Charley JonesBarrington Research Associates, Inc.
Ravi MisraBerenberg